Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Synaptogenix Inc. Common Stock is a biotechnology business based in the US. Synaptogenix shares (SNPX) are listed on the NASDAQ and all prices are listed in US Dollars. Synaptogenix employs 4 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $7.85 |
|---|---|
| 52-week range | $4.40 - $14.50 |
| 50-day moving average | $9.41 |
| 200-day moving average | $8.99 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.65 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.85 from 2022-01-21
| 1 week (2022-01-14) | -12.39% |
|---|---|
| 1 month (2021-12-23) | -10.95% |
| 3 months (2021-10-22) | -20.47% |
| 6 months (2021-07-23) | -35.12% |
| 1 year (2021-01-22) | 30.83% |
|---|---|
| 2 years (2020-01-19) | N/A |
| 3 years (2019-01-19) | N/A |
| 5 years (2017-01-19) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -23.05% |
| Return on equity TTM | -38.31% |
| Profit margin | 0% |
| Book value | $5.11 |
| Market capitalisation | $59.8 million |
TTM: trailing 12 months
We're not expecting Synaptogenix to pay a dividend over the next 12 months.
Synaptogenix's shares were split on a 1:4 basis on 18 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synaptogenix shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Synaptogenix shares which in turn could have impacted Synaptogenix's share price.
Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York. .
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.